Objectives: To assess the risks and benefits of levosimendan in acute decompensated heart failure compared to dobutamine or placebo. Methods: Pubmed, the Cochrane Central Register of Controlled Trials (CENTRAL), the European Heart Journal, and the Journal of the American College of Cardiology and Circulation were searched for randomized clinical trials of a 24 h IV infusion of levosimendan compared to dobutamine or a placebo in patients ≥18 years old admitted with a diagnosis of acute decompensated heart failure of any etiology with a NYHA class III and IV heart failure, a left ventricular ejection fraction <0.35, pulmonary catheter wedge pressure >15 mmHg or cardiac index <2.5 ml/min/m 2 . Results: Eleven clinical trials (2747 patients) met the inclusion criteria for this review. Levosimendan was associated with a significant increase in NYHA class OR 3.06 (95% CI 1.23---7.59; p = 0.02), and a tendency to improve fatigue OR 1.80 1.53 (IC95% 0.99---2.39, p = 0.06) and clinical improvement composite OR 1.20 (IC95% 0.99---1.46; p = 0.06), as compared to dobutamine or a placebo. Conclusions: Levosimendan in acute decompensated heart failure improves NYHA functional class, LVEF and BNP levels when compared to dobutamine or a placebo, with an increase in side effects.
Introduction
Heart failure (HF) is a clinical syndrome derived from any structural alteration or cardiac function which leads to the inability of the heart to deliver oxygen at the rate metabolically active tissue require unless it does so at the expense of an increase in ventricular inflow pressure. 1, 2 Thus, HF has been divided into heart failure with preserved ejection fraction or diastolic heart failure (HFpEF), and heart failure with reduced ejection fraction or systolic heart failure (HFrEF), although it would also always be possible to differentiate it based on the time of onset or evolution (acute or chronic), severity, clinical stage or symptom direction (anterograde or retrograde) whichever predominates in the syndrome. HFpEF prevalence varies from 40 to 71%; nonetheless, this depends on the great variability of the ejection fraction cutoff criteria to classify it. 1, 2 Close to 1---2% of adult population have HF, with a prevalence which may be greater than 10% in people over 70 years of age. 3 Heart failure decreases quality of life by increasing morbidity and mortality due to frequent hospitalizations caused by acute decompensation or intensification. It can also be the main cause of hospitalization in individuals over 65 years of age. This not only represents an increase in the cost of heart failure treatment, but it is also a prognosis marker in the course of the disease, since mortality linked to acute decompensation may be up to 10% at 60 days, with a rate of new hospitalizations in the following 6 months of 50% and a mortality of 30% at 1 year. 2, 4, 5 Acute decompensated heart failure is defined as the sudden or gradual onset of the signs and symptoms of heart failure, which requires an unplanned visit to the doctor's office or the emergency unit, or in some cases, hospitalization. Regardless of the precipitating causes of the exacerbation, the universal finding in decompensated HF is the rise in intracavitary filling pressure, with the resulting systemic and pulmonary congestion. 6 There is no widely accepted nomenclature for HR syndromes which require hospitalization. ''Acute HF'' or ''acute HF syndrome'' or ''acutely decompensated HF'' have been used indistinctly. Even though the latter term has a greater acceptance, its main limitation is that it does not distinguish between a first timer or a previously stable HF with acute worsening. Patients who are hospitalized due to HF may be classified depending on their etiology in those with acute myocardial ischemia, accelerated arterial hypertension, acutely decompensated HF, cardiogenic shock and decompensated right heart failure. 2 Most patients with decompensated HF admitted to the hospital suffer a worsening of their chronic HF. Between 15 and 20% represent new HF diagnoses. Close to 50% have an ejection fraction ≤40%. This group has a high prevalence of the atheromatous coronary disease (60%), fibrillation or atrial flutter (30---46%), valvular heart disease (44%) and dilated cardiomyopathy (25%), all according to the chronicity of the subjacent disease. 7 Treatment goals for decompensated HF are an improvement of symptoms and hemodynamic deterioration and the reduction of morbidity and mortality. Modern treatments have improved prognosis, reducing the risk of a new hospitalization by up to 30---50%, with significant changes in mortality. 8 In this sense, calcium sensitizers, unlike adrenergic agonists, increase myocardial contractility with a minimal energy consumption and a lower risk of arrhythmias, with an improvement in mortality and hemodynamic parameters. 9, 10 Levosimendan, an agent in the group of calcium sensitizers, has inotropic and vasodilator (inodilator) effects which improve myocardial work without a change in oxygen consumption. This is produced by the opening of ATPdependent K + channels in the myocyte and smooth vascular muscle cells, thus causing vasodilation with pre-charge and post-charge reduction and an increase in coronary flow. 11 Moreover, it has a positive chronotropic effect caused by the increase of Ca 2+ sensitivity on behalf of contractile proteins, a characteristic which determines an increase in myocardial force without alteration, ventricular diastolic relaxation or induced cell death. 12, 13 There are different publications comparing Levosimendan with other inotropic drugs which have been proven to show an improvement in mortality, hemodynamic parameters and biochemical parameters in favor of levosimendan; however, not much is known about the change in parameters of symptom improvement as the main objective of HF treatment. The main objective of this systemic review and meta-analysis is to evaluate whether or not levosimendan offers a benefit in symptomatic improvement versus dobutamine and/or a placebo.
Methods

Patients
Adults ≥18 years of age, admitted to the hospital due to decompensated heart failure of any etiology, in the NYHA (New York Heart Association) III or IV functional class, a left ventricular ejection fraction (LVEF) <0.35, a pulmonary wedge pressure (PWP) ≥ 15 mmHg or a cardiac index <2.5 L/min/m 2 .
Included studies
Randomized clinical trials (control or placebo) with a priori well-defined primary outcome which did not have more than a 10% loss during follow up.
Intervention
Intravenous infusion of levosimendan for 24 h, compared with placebo and/or dobutamine.
Objectives
• Primary: Clinical improvement of dyspnea, fatigue, NYHA functional class and combined terminal point of clinical improvement (dyspnea, fatigue, and NYHA functional class).
• Secondary: Improvement of hemodynamic parameters (LVEF, heart index or cardiac output [CO] ) and pulmonary wedge pressure, brain natriuretic peptide (BNP), total mortality, adverse effects and the use of rescue Figure 1 Flowchart of the trials included in the systematic review. treatment, defined as use of positive inotropes or intravenous vasodilators, which were not part of the analyzed medications (i.e. dopamine or norepinephrine).
Exclusion criteria
Duplicated trials, trials which were in a language other than Spanish or English, trials that did not have relevant information to measure the primary outcome, nonrandomized clinical trials and articles that were not available in full text format were excluded.
Search parameters to identify the studies
Relevant clinical trials were found by electronic search in MEDLINE (1966 to August 2013), in the platforms of Pubmed, 
Selection and extraction of studies
Tw o authors reviewed the abstracts to identify potential clinical trials. If the summary met the inclusion criteria, the study was considered for a full-text review. Full-text articles were extracted and evaluated for validity and quality by both authors to determine if they met the eligibility criteria specified. When one of these was unclear, the study was not accepted for review.
Statistics
Meta-analytic techniques were used to increase the power of hypothesis testing and also to obtain information not available in individual trials. Using the effect methods for each model, we calculated the value of their statistical association and their corresponding chi-square. The chi-square of homogeneity, calculated as the difference between the total chi-square and the association of the chi-square, allowed us to measure the degree of homogeneity among the association values to be evaluated. The results were expressed as relative risk, odds ratio or difference from the standardized mean, with a 95% confidence interval. To carry out the statistical calculations and the meta-analytical graphs, we used Review Manager version 5.2, which provided us with the Cochrane Collaboration.
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Level of significance
Association: Only the least significant p-value of the association test should be taken into consideration; for the conclusion, the level of significance was proposed at p = 0.05. Heterogeneity: Because statistical tests lack the power to measure heterogeneity in a meta-analysis, a level of statistical significance of p = 0.10 was used.
Results
Description of the studies
The main features of the included studies and patients are summarized in Tables 2 and 3. 15--- 24 The description of the data of each included trial can be consulted in Tables 5---15. 15--- 24 Of the 363 references to potential clinical trials initially selected, only 11 randomized clinical trials met the inclusion criteria and were included in the qualitative and quantitative analysis, including a total of 2747 patients in the analysis (Fig. 1) . The reasons for excluding the 45 full-text references are summarized in Table 16 . Levosimendan with bolus of 6 g/kg, infusion of 0.1 g/kg/min per 1 h. Hourly boluses of 6 g/kg and infusion titration of 0.1 g/kg/min every hour up to 0.4 g/kg/min. At the end of 6 h, half of the dose was continued for 24 h and at the end of 24 h, it was re-randomized 1: 1 for infusion for the remaining 24 h. Outcomes Changes in hemodynamic measures, symptoms, plasma concentration of metabolites of levosimendan, adverse effects and death. Notes
The primary outcome is not established, the losses of group 1 during the first 24 h are not commented. Interventions Group 1: Levosimendan with bolus of 24 g/kg in 10 min, followed by continuous infusion for 24 h of 0.1 g/kg/min with a double increase every 2 h until reaching goal of improvement of the cardiac index > 30% with possibility to decrease to the half or suspend for major limiting or cardiovascular events Control group: Continuous infusion of 5 mcg/kg/min for 24 h without loading dose, with an increase in dose twice every 2 h until reaching goal of improvement of the cardiac index >30% with the possibility of halving or suspending by events Limiting or cardiovascular diseases Outcomes Primary: Proportion of patients with improvement of hemodynamic parameters at the end of 24 h (Improvement of >30% in cardiac index or decrease of ≥25% in PWP) Secondary: Changes in hemodynamic parameters other than cardiac index and PWP from baseline to 24 h, changes in symptoms of heart failure (dyspnea and fatigue) assessed by the patient on a scale of four (much better, slightly better, unchanged, worse) from baseline up to 24 h, proportion of patients requiring rescue therapy with positive inotropes, vasodilators or diuretics, number of days alive and out of hospital and without intravenous drugs in the first month, time to develop worsening of heart failure and death. Safety: Spontaneous reports of adverse reactions, laboratory tests and all-cause mortality at 31 and 180 days. Levosimendan with a bolus of 6 g/kg, followed by continuous infusion, initially at 0.1 g/kg/min. A bolus of 6 g/kg was repeated every hour at the rate of infusion, increasing 0.1 g/kg/min until 0.4 g/kg/min or until some limiting event Outcomes
Risk of bias
Changes in hemodynamic parameters, symptoms (dyspnea and fatigue) and adverse events. Notes
The primary outcome is not established. There was no relevant clinical data for the primary outcome As in most of the studies on HF we analyzed, the inclusion criteria were that patients be in the NYHA III or IV functional class, with an LVEF below 35% measured by two-dimensional echocardiography or radionuclide ventriculography, a PWP > 15 mmHg and a cardiac index < 2.5 L/min/m 2 . The mean age of the patients was 63 ± 4.2 years, 81.9 ± 8.8% were men and the mean LVEF was 21 ± 1.7%. The etiology of heart failure was ischemic in 62.9 ± 16.9% and non-ischemic in 35.7 ± 17.4%. The most common concomitant treatments were ACE inhibitors, angiotensin II receptor antagonists (ARBs), ␤-blockers and diuretics.
Risk of bias in included studies
We included 7 double-blind clinical trials and 4 open-label studies. 16, 18, 20, 21 The randomization method was described 19,24 The primary outcome was described in 4 trials, including 2230 patients (79.7% of all patients). 19, 22, 24 Results of the meta-analysis Table 4 ). There was substantial heterogeneity (p < 0.10) in all primary outcomes (Fig. 2) .
Outcomes of clinical improvement
Secondary outcomes
There was no difference in mortality between the levosimendan group and the placebo or dobutamine groups (RR 0.92, 95% CI 0.74---1.14, p = 0.43), although there was a significant improvement in LVEF (RR of 4.07, 95% RR = 95% CI −358.32 to −292.89; p < 0.00001), in the incidence of new episodes of heart failure (RR 0.83, 95% CI 0.70---0.97, p = 0.02) and in the use of rescue treatment (RR 0.63 95% CI 0.48---082, p = 0.0007) (Fig. 3) . The following adverse events were more commonly observed in the levosimendan group compared to the placebo or dobutamine groups: headache (RR 1.88, 95% CI 1.51---2.34, p < 0.00001), hypotension (RR 1.38, 95% CI 1.17---1.64; RR 1.43, 95% CI 1.08---1.89, p = 0.01), (Fig. 4) .
Discussion
There are few randomized clinical trials that report the outcomes of symptomatic improvement, and among them, the majority only report the NYHA functional class. However, it is important to note that they do not consider the limitations associated with fatigue, palpitations, dyspnea or angina, and therefore, there are no reports of the improvement of these individual symptoms in the trials. Thus, because patients with HF most often present a pivotal symptom, it is important to know if an intervention, in this case, levosimendan, will improve a specific symptom to a certain extent. In this meta-analysis evaluating the intermittent administration of levosimendan against placebo in chronic HF, we conclude that NYHA functional class ≥ 3 is similar in survivors of both groups. 24 Contrary to previous findings, the present meta-analysis demonstrates a statistically significant improvement in the NYHA functional class, although only through a trend toward improvement in fatigue outcomes and the combined endpoint of clinical improvement in favor of levosimendan when compared to placebo or dobutamine. To this extent, a larger sample is required to reduce the confidence interval of the outcomes.
In a systematic review with a meta-analysis, Ribeiro, et al. concluded that there was no significant difference in mortality in patients with decompensated HF treated with a levosimendan infusion when compared to dobutamine or placebo. 25 However, there are other meta-analyses that report a benefit in mortality in favor of levosimendan in critically ill patients, patients undergoing cardiac surgery with an ejection fraction <0.40 and in acute heart failure.
26---29
The present meta-analysis did not show a significant difference in mortality when comparing levosimendan with placebo or dobutamine. However, an improvement in LVEF, Figure 4 Adverse events outcomes B-type natriuretic peptide (BNP) levels and a decrease in new heart failure events and the use of salvage therapy in favor of levosimendan was shown, with a statistically significant difference.
Regarding the adverse effects analyzed, some reports of meta-analyses show no difference between levosimendan and dobutamine in hypotension, supraventricular arrhythmias, and ventricular arrhythmias.
Although other systematic reviews have reported a trend toward hypotension against levosimendan and a reduction of postoperative atrial fibrillation in favor of levosimendan, in the present meta-analysis there were fewer headaches, cases of hypotension, non-sustained ventricular tachycardia, and atrial fibrillation in favor of placebo or dobutamine, with significant differences.
27,28
Conclusions
This systematic review and meta-analysis showed an improvement of the NYHA functional class and other combined points of clinical improvement, but not of the simple outcomes of dyspnea or fatigue in patients with decompensated heart failure when levosimendan was used compared to placebo or dobutamine. In addition, it demonstrated an improvement in other prognostic markers of HF, such as LVEF, serum BNP level and reduction in the use of rescue treatments during the exacerbation of HF. However, it is important to mention that the side effects associated with levosimendan may limit its use.
The main limitation of this review was the lack of standardization of the reporting of outcomes of clinical improvement, adverse effects, and follow-up times in the controlled trials used for the meta-analysis.
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